# Evaluation of Risk Factors associated with Development of Catheter-associated Venous Thromboembolism in Pediatric ICU Patients



Matthew Wong, MS4<sup>1</sup>, Ryan Good, MD<sup>1,2</sup>, John Kim, MD<sup>1,2</sup>

<sup>1</sup>University of Colorado School of Medicine, <sup>2</sup>Department of Pediatrics – Critical Care Medicine, University of Colorado



# Background

- Central venous lines (CVL) are a major risk factor for the development of Venous thromboembolisms (VTEs) in pedatric patients
- Other factors previously found to have increased risk of VTE in pediatric patients include age under 1 year, usage of mechanical ventilation, recent surgery, and a primary diagnosis category of an oncologic, cardiac, or hematologic cause
- Pediatric patients requiring an ICU level of care often have a necessity for a CVL such as a CVC, PICC, or hemodialysis catheter
- Identification of additional factors associated with a higher risk of developing catheter-associated VTE (CA-VTE) will aid in increased identification of patients at higher risk of developing CA-VTE, allowing for increased vigilance of clinical signs of VTE in these patients

## Objective

To identify factors, if any, that increase a pediatric patient with a CVL's risk of developing a CA-VTE

# Methods

- Retrospective chart review of all patients at the CHCO PICU from 1/1/2016 to 12/31/2020
- Patients included who had a PICC, CVC, or hemodialysis catheter placed by either the PICU or a CHCO surgical team during their PICU admission, and who had a radiology-reviewed ultrasound of the extremity with the CVL
- Ultrasound must have been performed between time of CVL placement up to three days after removal of the line
- Patients with multiple CVLs and assessment of multiple limbs for CA-VTE were treated as multiple cases, with each possible CA-VTE counting as one case
- VTE was determined by positive diagnosis on formal radiology read of ultrasound

## Results

- Patient Population: 210 cases from 169 patients were found to meet study criteria
- Univariate analyses was run for factors related to the clinical characteristics of the study population, as well as characteristics of the CVL itself

| Demographic Variable                      | No CA-VTE  | CA-VTE     |
|---|------------|------------|
| # Patients,                               | 112        | 98         |
| Age in years (range)                      | 0.06-17.99 | 0.18-17.66 |
| Weight, kg (range)                        | 3.8-106.9  | 3.22-151.0 |
| Male sex (%)                              | 59.82%     | 50.0%      |
| Race (%)                                  |            |            |
| White                                     | 45.54%     | 48.98%     |
| Black or African American                 | 1.79%      | 3.06%      |
| Asian                                     | 3.57%      | 1.02%      |
| Hispanic/Latino                           | 24.11%     | 24.49%     |
| Native Hawaiian or other Pacific Islander | 1.79%      | 1.02%      |
| American Indian or Alaska Native          | 2.68%      | 0%         |
| Mixed/Other                               | 10.71%     | 11.22%     |
| Unspecified                               | 9.82%      | 10.2%      |

| Characteristic      |  | CA-VTE Univariate Analysis |     |       |                  |           |       |            |        |
|---------------------|--|----------------------------|-----|-------|------------------|-----------|-------|------------|--------|
|                     |  | No                         | Yes | Total | Relative<br>Risk | 95%       | Sig   | NNT (Harm) | Z stat |
| CVL Type            |  |                            |     |       |                  |           |       |            |        |
|                     | PICC                                     | 50                         | 42  | 92    | 1.00             |           |       |            |        |
|                     | CVC                                      | 54                         | 53  | 107   | 1.08             | .81-1.46  | .5831 | 25.77      | 0.544  |
|                     | Hemodialysis/<br>plasmapheresis Catheter | 8                          | 3   | 11    | .597             | .22-1.61  | .3080 | 5.441      | 1.019  |
| CVL Location        |  |                            |     |       |                  |           |       |            |        |
|                     | Femoral                                  | 48                         | 47  | 95    | 1.00             |           |       |            |        |
|                     | IJV                                      | 9                          | 7   | 16    | .8846            | .49-1.6   | .6838 | 17.47      | .407   |
|                     | Subclavian                               | 4                          | 3   | 7     | .86              | .36-2.08  | .748  | 15.114     | .32    |
|                     | Brachial                                 | 17                         | 11  | 28    | .794             | .48-1.31  | .3692 | 9.815      | .898   |
|                     | Cephalic                                 | 2                          | 4   | 6     | 1.35             | .74-2.46  | .3309 | 5.816      | .972   |
|                     | Basilic                                  | 31                         | 26  | 57    | .922             | .65-1.3   | .6481 | 25.9       | .456   |
|                     | Other                                    | 1                          | 0   | 1     |                  |           |       |            |        |
| Number of Lumens    |  |                            |     |       |                  |           |       |            |        |
|                     | 1  | 17                         | 13  | 30    | .85              | .55-1.32  | .4661 | 13.03      | .729   |
|                     | 2  | 73                         | 76  | 149   | 1.00             |           |       |            |        |
|                     | 3  | 22                         | 9   | 31    | .569             | .32-1.01  | .0537 | 4.551      | 1.93   |
| CVL Duration (days) |  |                            |     |       |                  |           |       |            |        |
|                     | 0-7                                      | 52                         | 62  | 114   | 1.00             |           |       |            |        |
|                     | 8-14                                     | 17                         | 20  | 37    | .994             | .70-1.4   | .972  | 301.28     | .035   |
|                     | 15-21                                    | 9                          | 9   | 18    | .919             | .56-1.5   | .737  | 22.8       | .335   |
|                     | 22 and up                                | 7                          | 34  | 41    | 1.53             | 1.22-1.89 | .0001 | 3.504      | 3.79   |

# Significant Findings

- The clinical characteristics of: primary diagnosis category of malignancy (RR 1.74, 95% CI 1.18-2.55), and primary diagnosis category of trauma (RR 1.47, 95% CI 1.01-2.15) caused a statistically significant increase in the risk of developing CA-VTE
- The CVL characteristic of CVL duration greater than 22 days was associated with a statistically significant increase (RR 1.53, 95% CI 1.22-1.89) in risk of development of CA-VTE.

| Condon                            | Characteristic    |                |           |           | Univariate Analysis |                               |                   |                    |                       |
|-----------------------------------|-------------------|----------------|-----------|-----------|---------------------|-------------------------------|-------------------|--------------------|-----------------------|
| Gender                            |                   | No             | Yes       | Total     | RR                  | 95% CI                        | Sig               | NNT<br>(Harm)      | Z stat                |
|                                   | Female            | 45             | 49        | 94        | 1.23                | 0.93-<br>1.65                 | P = 0.1521        | 10.12              | 1.432                 |
|                                   | Male              | 67             | 49        | 116       | 1.00                |                               |                   |                    |                       |
| History of VTE                    | Yes               | 4              | 4         | 8         | 1.07                | 0.53-<br>2.18                 | P = 0.8425        | 28.86              | 0.199                 |
|                                   | No                | 108            | 94        | 202       | 1.00                |                               |                   |                    |                       |
| Surgery within 24 hrs o           | of Line Placement |                |           |           |                     |                               |                   |                    |                       |
|                                   | Yes               | 20             | 18        | 38        | 1.02                | .70-1.48                      | P= 0.9233         | 116.71             | .096                  |
|                                   | No                | 92             | 80        | 172       | 1.00                |                               |                   |                    |                       |
| Primary Diagnosis Cate            |                   | 2              | 0         | 12        | 1 74                | 1 10                          | D- 0 0050         | 2 4 4 7            | 2 704                 |
|                                   | Malignancy        | 3              | 9         | <b>12</b> | 1.74                | 1.18-<br>2.55                 | P= 0.0052         |                    | 2.794                 |
|                                   | Infection  Trauma | 28<br><b>8</b> | <b>14</b> | <b>22</b> | 1.02<br>1.47        | 0.69-<br>1.48<br><b>1.01-</b> | P= 0.9255<br>P =  | 128.26<br>4.898    | 0.093<br><b>2.008</b> |
|                                   | Hematologic       | 6              | 2         | 8         | 0.58                | 2.15<br>0.17-                 | <b>0.0446</b> P = | <b>4.898</b> 5.488 | .881                  |
|                                   | Other             | 67             | 51        | 118       | 1.00                | 1.96                          | 0.3783            | 3.400              | .001                  |
| History of Congenital F           |                   | 07             | 31        | 110       | 1.00                |                               |                   |                    |                       |
| Thistory of Congenitari           |                   | 4-             | 1.0       | 24        | 4.40                | 77.4.64                       | 5 0 5044          | 17.000             | 524                   |
|                                   | Yes               | 15             | 16        | 31        | 1.13                | .77-1.64                      | P= 0.5344         | 17.233             | .621                  |
|                                   | No                | 97             | 82        | 179       | 1.00                |                               |                   |                    |                       |
| Interventions within 24 placement | 4 nrs of CVL      |                |           |           |                     |                               |                   |                    |                       |
| Transfusion (Any blood products)  | Yes               | 61             | 41        | 102       | 0.76                | .567-<br>1.02                 | P = 0.0718        | 7.948              | 1.801                 |
|                                   | No                | 51             | 57        | 108       | 1.00                |                               |                   |                    |                       |
| TPN                               | Yes               | 32             | 25        | 57        | 0.92                | .656-<br>1.29                 | P= 0.6247         | 25.955             | .489                  |
|                                   | No                | 80             | 73        | 153       | 1.00                |                               |                   |                    |                       |
| Use of Vasoactive Medications     | Yes               | 68             | 54        | 122       | 0.89                | .66-1.18                      | P= .4078          | 17.429             | .828                  |
|                                   | No                | 44             | 44        | 88        | 1.00                |                               |                   |                    |                       |
| Anticoagulation                   | Yes               | 45             | 35        | 80        | 0.90                | 0.67-<br>1.23                 | P= 0.5113         | 21.224             | .657                  |
|                                   | No                | 67             | 63        | 130       | 1.00                |                               |                   |                    |                       |
| Mechanical<br>Ventilation         | Yes               | 98             | 86        | 184       | 1.01                | .65-1.58                      | P= 0.9555         | 170.86             | 0.056                 |
|                                   | No                | 14             | 12        | 26        | 1.00                |                               |                   |                    |                       |
| Plasmapheresis                    | Yes               | 8              | 8         | 16        | 1.08                | .65-1.80                      | P= 0.7747         | 27.714             | 0.286                 |
|                                   | No                | 104            | 90        | 194       | 1.00                |                               |                   |                    |                       |
| CVVHD                             | Yes               | 16             | 7         | 23        | 0.6254              | .33-1.18                      | P= 0.1475         | 5.486              | 1.448                 |
|                                   |                   | 96             | 91        | 187       | 1.00                |                               |                   |                    |                       |

## Conclusions

Placement of a central venous line (CVL) is a major risk factor for the development of VTE in children. Increased duration of catheter placement and primary conditions of oncologic and traumatic nature were found to have increased risk of Identifying additional risk factors that further increase this risk can aid in decreasing the rate of CA-VTE in critically ill children.

### **Future Plans**

 This project is intended to continue with a plan for analysis of the measures of catheter-to-vein ratio (CVR) against catheter-to-vein difference (CVD) as predictors of the development of CA-VTE for pediatric patients, as CVR was developed as a predictor for adult patients, and CVD is a newer measure that has not been assessed as robustly as CVR.

#### References

- 'Central venous line-related thrombosis in children: association with central venous line location and insertion technique', Male C et al. Blood. 2003;101(11):4273-4278.
- 2. 'Intravascular Complications of Central Venous Catheterization by Insertion Site', Parienti JJ et al. New England Journal of Medicine. 2015;373(13):1220-1229.
- 3. 'Identification of a "VTE-rich" population in pediatrics Critically ill children with central venous catheters', Tran M et al. Thrombosis Research. 2018;161(1):73-77.
- 4. 'Incidence and risk factors associated with venous thrombotic events in pediatric intensive care unit patients', Higgerson RA et al. Pediatric Critical Care Medicine. 2011;12(6):628-634.
- 5. 'Which central venous catheters have the highest rate of catheter-associated deep venous thrombosis: a prospective analysis of 2,128 catheter days in the surgical intensive care unit', Malinoski D et al. Journal of
- Trauma and Acute Care Surgery. 2013;74(2):454-462.

  6. 'Characterization of central venous catheter-associated deep venous thrombosis in infants', Gray BW et al.
- Journal of Pediatric Surgery. 2012;47(6):1159-1166.
  7. 'Central Venous Catheter-related Deep Vein thrombosis in the Pediatric Cardiac Intensive Care Unit', Steen
- EH et al. The Journal of Surgical Research. 2019;241(1):149-159.

  8. 'Incidence and risk factors of catheter-related deep vein thrombosis in a pediatric intensive care unit: a
- prospective study', Beck C et al. The Journal of Pediatrics. 1998;133(2):237-241.
- 9. 'Central venous catheter-related thrombosis', Geerts, W. New Paradigms in Anticoagulation and Thrombolysis. 2014 (1):306-311.
- 10. 'Peripherally inserted central venous catheters and central venous catheters related thrombosis in post-critical patients', Bonizzoli M, et al. Intensive Care Medicine. 2011;37(1):284-289.
- 11. 'Central venous lines in critically ill children: Thrombosis but not infection is site dependent', Derderian SC, et
- al. Journal of Pediatric Surgery. 2019;54(9):1740-1743.

  12. 'Peripherally Inserted Central Catheter (PICC)-related Thrombosis in Critically III Patients'. Zochios V et al. The
- Journal of Vascular Access. 2014;15(5):329-337.
- 13. 'Routine surveillance ultrasound for the management of central venous catheters in neonates', Haddad H, et al. The Journal of Pediatrics. 2014;164(1):118-122.
- 14. 'Complications of femoral and subclavian venous catherization in critically ill patients: a randomized controlled trial', Merrer J et al. Journal of the American Medical Association. 2001;286(6):700-707.
- 15. 'Risk Factors for Upper Extremity Venous Thrombosis Associated with Peripherally Inserted Central Venous Catheters'. Marnejon T et al. The Journal of Vascular Access. 2012;13(2):231-238.
- 16. 'Predictive Risk Factors of Venous Thromboembolism (VTE) associated with peripherally inserted central catheters (PICC) in ambulant solid cancer patients: retrospective single Centre cohort study', Al-Asadi O, et
- 17. 'Hemodialysis Catheter-related Central Venous Thrombosis: Clinical Approach to Evaluation and
- Management', Gunawansa N et al. Annals of Vascular Surgery. 2018; 51(1):298-305. 18. 'Intravenous catheter', Evans NS, et al. Vascular Medicine. 2018;23(4):411-413.
- 19. Sharp R, Cummings M, Fielder A, Mikocka-Walus A, Grech C, Esterman A. The catheter to vein ratio and rates of symptomatic venous thromboembolism in patients with a peripherally inserted central catheter (PICC): a prospective cohort study. *Int J Nurs Stud*. 2015;52(3):677-685. doi:10.1016/j.ijnurstu.2014.12.002
- 20. Schmidt B, Andrew M. Neonatal thrombosis: report of a prospective Canadian and international registry. *Pediatrics*. 1995;96(5 Pt 1):939-943.

# Acknowledgements

I would like to thank my mentors Dr. John Kim and Dr. Ryan Good, as well as Dr. Cecilia Low Wang, for their guidance and kindness during this project.